Delving into the Latest Updates on Chlamydia infection mRNA vaccine (Sanofi) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, mRNA vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesUrogenital Diseases

Active Indication

Chlamydia trachomatis infection

Inactive Indication-

Originator Organization

Sanofi SA

Active Organization

Sanofi

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

RegulationFast Track (United States)

Login to view timeline

The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to 29 years.
This study will consist of 3 Sentinel Cohorts and a Main Cohort, with the Sentinel Cohorts assessing the safety of the different dose levels in a stepwise manner.
All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected duration of the participant's involvement will be 18 months.

Start Date27 Mar 2025

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Chlamydia infection mRNA vaccine (Sanofi)

Login to view more data

100 Translational Medicine associated with Chlamydia infection mRNA vaccine (Sanofi)

Login to view more data

100 Patents (Medical) associated with Chlamydia infection mRNA vaccine (Sanofi)

Login to view more data

100 Deals associated with Chlamydia infection mRNA vaccine (Sanofi)

Login to view more data